Chat with Filing

Ask questions about this document

Please log in or register to use the chat feature. Please register first.

EGM - BAI_Publication of the Revised Agenda for the 2024 AGM_FINAL_17.04.24

Company: BenevolentAI Date: 2024-04-17 Language: English Register to download

Loading document preview...

Document Preview Not Available

The file type (.pdf) cannot be displayed directly here.

Open Original File

Error loading document preview. Please try the 'Open Original File' link.

You're One Click Away From The Full Filing

Instantly access this document—and 2.8M more—for free. Select your preferred method:

Continue with Google Continue with Microsoft Continue with Facebook Continue with Amazon

![](_page_0_Picture_0.jpeg)

# **BenevolentAI**

#### **Publication of the Revised Agenda for the 2024 AGM**

**LONDON, UK, 17 APRIL 2024:** BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces the publication of the Revised Agenda for its Annual General Meeting set to be held on 2 May 2024 at 14:00 CEST at 2, place Winston Churchill, L-1340 Luxembourg (the "2024 AGM") (the "Revised Agenda").

The Revised Agenda, the revised proxy form and all other meeting documentation are now available on the Company's website [\(www.benevolent.com/investors/general-meetings/\)](http://www.benevolent.com/investors/general-meetings/) and at the Company's registered office.

The shareholders entitled to participate and vote at the 2024 AGM will be those who are shareholders on the record date of 18 April 2024 at 24:00 (midnight) CEST.

## **Enquiries:**

## **Investors:**

Fleur Wood – VP Investor Relations [fleur.wood@benevolent.ai](mailto:fleur.wood@benevolent.ai) [investors@benevolent.ai](mailto:investors@benevolent.ai) T: +44(0) 203 781 9360

#### **Company Secretary:**

Judit Molnar – Deputy Company Secretary cosec@benevolent.ai T: +44(0) 203 781 9360

## **About BenevolentAI**

At BenevolentAI (AMS: BAI), we serve patients by leveraging our proprietary and validated Benevolent PlatformTM that integrates AI and science to uncover new biology, predict novel targets and develop first-inclass or best-in-class drugs for complex diseases. By applying proprietary advanced AI tools, in combination with in-house scientific expertise and wet-lab facilities, BenevolentAI is well-positioned to identify and accelerate novel drug discovery. The Company's business model presents multiple routes for value creation including discovery collaborations with pharma companies like AstraZeneca and Merck, advancing in-house pipelines to inflection points, and commercialising a suite of knowledge exploration tools. Headquartered in London, with wet labs in Cambridge (UK) and an office in New York, BenevolentAI is at the forefront of reshaping the future of drug discovery and delivering innovative medicines.

Unlock Europe's Largest Financial Database—Free

Get instant access to over 2.8M filings from 8,970 companies across 44 markets. No cost. No hassle. Just results.

Save hours with instant data access
Trusted by leading financial institutions
Free forever—no strings attached

Or sign up with

Google Microsoft

Or log in with

Google Microsoft

This premium feature is designed for professionals. Upgrade your plan to gain immediate access and enhance your research capabilities.

Upgrade Now